

Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment

NCT06683950

Status	RECRUITING
Phase	Phase 4
Sponsor	Kim's Eye Hospital
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (9)

- Willing, committed, and able to return for ALL clinic visits and complete all study related procedures.
 - Able to read, (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member) understand and willing to sign the informed consent form.
 - Signed informed consent
 - Patients aged 50 years or older
 - Patients diagnosed with neovascular AMD or PCV
- ... and 4 more (see full listing online)

Exclusion (20)

- Any prior ocular (in the study eye) or systemic treatment or surgery for neovascular AMD except dietary supplements or vitamins.
 - Significant media opacities, including cataract, in the study eye that might interfere with visual acuity, assessment of safety, or fundus photography.
 - Any concurrent ocular condition in the study eye which, in the opinion of the investigator, could either increase the risk to the patient beyond what is to be expected from standard procedures of intraocular injection, or which otherwise may interfere with the injection procedure or with evaluation of efficacy or safety.
 - Any ocular or periocular infection within the last 2 weeks prior to Screening in either eye.
 - Any history of uveitis in either eye.
- ... and 15 more (see full listing online)

Locations (1 total)

Kim's Eye Hospital, Seoul, Seoul, South Korea